Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report


Camci C., Sevinc A., Aslan Y., Kalender M. E. , Buyukberber S.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.63, sa.4, ss.745-748, 2009 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Konu: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1007/s00280-008-0775-x
  • Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Sayfa Sayıları: ss.745-748

Özet

Background Ovarian cancer remains one of the most lethal of all gynecologic malignancies, accounting for more deaths than cervical and uterine cancer combined. Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses. However, despite aggressive surgery and chemotherapy, more than 80% of patients will relapse and will then be treated with second line chemotherapy with objective responses in about 20% of patients and even lower percentages of complete responses.